Spotlight Medical, a Paris-based oncology diagnostics company, today announced that myStage Dx has received CE marking under the European Union In Vitro Diagnostic Medical Devices Regulation (IVDR, ...

Performance evaluation of a reflex blood-based methylated ctDNA multi-cancer early detection test in individuals with obesity. A phase 1 study of intracerebroventricular (ICV) delivery of bivalent ...

Mumbai: A cancer prognostic test, developed by the family members of the late joint commissioner of police Himanshu Roy who ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the clinical availability of the ...

Myriad Genetics (MYGN) announced that its Prolaris prostate cancer prognostic test continues to be classified by the National Comprehensive Cancer Network, NCCN, as an ‘Advanced Tool’ in the fight ...

Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Telo Genomics Corp. (TELO:CA) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology ...

Telo Genomics Corp (TSE:TELO) has released an update. Telo Genomics Corp has revealed promising results for its TeloViewSMM prognostic test, which outperformed existing models in identifying high and ...

Managing the invisible: Treatment approaches after pathological complete response (pCR) to neoadjuvant chemotherapy in oral cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I ...

The use of Renalytix plc’s Kidneyintelx biomarker-based prognostic test led to increased and targeted use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients at risk of diabetic kidney ...

The hazard ratio (HR) for the primary endpoint was (3.84, p = 0.0009) in the first month The Prolocor pFCG™ test has the potential to help providers reduce 30-day readmission rates for Acute MI, an ...